Evaluation of the Compress Distal Femoral Replacement System

Patients in this study require a replacement of a lower thighbone and knee joint. A new device, called the ComPreSs, will be used in this study to replace the lower thighbone. This new device has not yet been approved by the Food and Drug Administration (FDA). There is not enough data to assure that it is as good as other devices currently available. Taking part in this study will help provide data to the FDA. Other devices used to replace large pieces of bone and joints in the leg can result in damage to the bone over time. The bone damage can cause the device to come loose from the bone. This is a bad problem, and causes pain, and often more surgery is needed. This new device connects to the bone in a different way to prevent some of the problems seen with other devices. The new device protects the bone, and may help the replacement last longer. So far, the device has been used in over 50 patients on a selective basis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lower Thighbone and Knee Joint Replacement

Age range

10 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Memorial Sloan Kettering Cancer Center

New York, 10065, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with bone tumors of the distal femur requiring primary bone resection of up to 30 cm with the resection at or below the lesser trochanter.
Patients with prior orthopaedic oncologic conditions requiring revisions of distal femoral replacement devices with a total replacement height of 30 cm or less and the resection level is at or below the lesser trochanter.
Patients who have a cortical bone thickness of 2.5 mm or larger in the region where the ComPreSs device would be implanted.
Patients diagnosed with a bone tumor classified as Stage 1A, IB, IIA, IIB, or III by Enneking's classification system. (See section 12.0, #7)

Exclusion criteria

Patients with active infection.
Patients who are unable to return for follow-up examinations.
Patients who have cortical bone thickness less than 2.5 mm in the region where the ComPreSs device would be implanted.
Patients who are unwilling or incapable of following postoperative care instructions.
Patients requiring bilateral knee implants.
Patients with evidence of vascular insufficiency (arterial and/or venous).
Patients having Parkinson's disease, severe muscular atrophy, neuromuscular disease in the affected limb.
Patients with prior irradiated bone.
Patients with metastatic cancer including carcinoma, melanoma, myeloma, lymphoma, leukemia.
Patients with pathologic soft tissue or skeletal conditions that would prevent secure fixation of the device in the bone.

Treatment and study plan

ComPreSs Distal Femoral Replacement System.

Device

ComPreSs system of intramedullary fixation along with the Finn Knee system

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Collaborators

Zimmer Biomet

Registry information

Important dates

Study start: 2000
Primary completion: 2009
Study completion: 2009
First posted: Jan 11, 2008
Registry last updated: Jun 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.